First-line levetiracetam versus enzyme-inducing antiseizure medication in glioma patients with epilepsy.

ABSTRACT:

Objective

This study aimed to directly compare the effectiveness of first-line monotherapy levetiracetam (LEV) versus enzyme-inducing antiseizure medications (EIASMs) in glioma patients.

Methods

In this nationwide retrospective observational cohort study, Grade 2-4 glioma patients were included, with a maximum duration of follow-up of 36 months. Primary outcome was antiseizure medication (ASM) treatment failure for any reason, and secondary outcomes were treatment failure due to uncontrolled seizures and due to adverse effects. For estimation of the association between ASM treatment and ASM treatment failure, multivariate cause-specific cox proportional hazard models were estimated, adjusting for potential confounders.

Results

In the original cohort, a total of 808 br

SUBMITTER: van der Meer PB 

PROVIDER: S-EPMC10100008 | biostudies-literature | 2023 Jan

REPOSITORIES: biostudies-literature